Viking Therapeutics (VKTX) Corporate presentation summary

VK2735 maintenance results

• In the maintenance study, 17.5 mg weekly produced 17.8% weight loss from baseline at Week 21; continued 17.5 mg weekly dosing reached 21.7% at Week 33, with no plateau observed.

• After transition from weekly dosing, participants maintained up to 96.7% of Week 21 weight loss with every-other-week dosing and up to 90.2% with monthly dosing through Week 33.

• Maintenance-phase GI AE rates were described as comparable to placebo; early discontinuation was 3% with every-other-week dosing and 5% with monthly dosing.

• The presentation positions flexible maintenance dosing as a potential long-term treatment approach; a subcutaneous-to-oral maintenance study is underway, with data expected in 2027.

VK2735 clinical development

• Two subcutaneous Phase 3 VANQUISH trials completed enrollment: VANQUISH-1 enrolled more than 4,500 participants and VANQUISH-2 approximately 1,000 participants with type 2 diabetes; data are expected in 2H27.

• In the 13-week subcutaneous VENTURE Phase 2 study, weight loss reached 14.7% from baseline at 15 mg; all doses were statistically significant versus placebo, with dose-dependent results.

• Oral VENTURE Phase 2 showed up to 12.2% mean weight loss after 13 weeks, progressive loss without a plateau, and maintenance-cohort proof of concept; Phase 3 SUNRISE trials began in 4Q26, with data expected in 2028.

• The oral Phase 2 presentation described 99% of GI-specific treatment-emergent AEs as mild or moderate; the subcutaneous-to-oral maintenance study is ongoing, with data expected in 2027.

Pipeline and market opportunity

• VK2735 is a dual GLP-1/GIP agonist being developed in injectable and oral formulations; the presentation cites a projected obesity market of $150B+ by 2035E and 18% CAGR.

• VK3019, an amylin agonist, entered Phase 1 in 2Q26; a Phase 1 multiple-ascending-dose study is planned for 2027.

• VK2809 completed the Phase 2b VOYAGE trial in MASH, with partnering discussions ongoing; VK0214 showed proof of concept in Phase 1b for X-ALD, also with partnering discussions ongoing.